Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Insulin Resistance Intervention After Stroke Trial (IRIS)

This study has been completed.
Sponsor:
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
Takeda Pharmaceuticals North America, Inc.
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00091949
First received: September 20, 2004
Last updated: January 6, 2016
Last verified: January 2016